Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial

Neeraj Agarwal, Arun Azad, Joan Carles, André P. Fay, Nobuaki Matsubara, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Fred Saad, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Matko Kalac, Dana A. Kennedy, Karim Fizazi